Three‑way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate‑resistant chronic myeloid leukemia patient

  • Authors:
    • Walid Al‑Achkar
    • Abdulsamad Wafa
    • Adnan Ikhtiar
    • Thomas Liehr
  • View Affiliations

  • Published online on: March 5, 2013     https://doi.org/10.3892/ol.2013.1228
  • Pages: 1656-1658
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic myelogenous leukemia (CML) is characterized by the Philadelphia (Ph) chromosome created by the reciprocal translocation t(9:22)(q34;q11), resulting in the chimeric gene breakpoint cluster region (BCR)‑Abelson (ABL). Variant Ph chromosome translocations involving chromosomes other than 9 and 22 occur in 5‑10% of CML cases. In the present study, a novel case of a Ph chromosome‑positive CML in the chronic phase (CP) is reported, with a three‑way Ph translocation involving three chromosomal regions, 9q34, 10p11.2 and 22q11.2, in addition to the loss of the Y chromosome, where the latter was a secondary abnormality. Since the majority of CML cases are currently treated with imatinib, variant rearrangements generally have no specific prognostic significance, although the mechanisms involved in resistance to therapy have yet to be investigated. The underlying mechanisms and prognostic implications of these cytogenetic abnormalities are discussed in the present study.
View Figures
View References

Related Articles

Journal Cover

May 2013
Volume 5 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Al‑Achkar W, Wafa A, Ikhtiar A and Liehr T: Three‑way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate‑resistant chronic myeloid leukemia patient. Oncol Lett 5: 1656-1658, 2013.
APA
Al‑Achkar, W., Wafa, A., Ikhtiar, A., & Liehr, T. (2013). Three‑way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate‑resistant chronic myeloid leukemia patient. Oncology Letters, 5, 1656-1658. https://doi.org/10.3892/ol.2013.1228
MLA
Al‑Achkar, W., Wafa, A., Ikhtiar, A., Liehr, T."Three‑way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate‑resistant chronic myeloid leukemia patient". Oncology Letters 5.5 (2013): 1656-1658.
Chicago
Al‑Achkar, W., Wafa, A., Ikhtiar, A., Liehr, T."Three‑way Philadelphia translocation t(9;10;22)(q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate‑resistant chronic myeloid leukemia patient". Oncology Letters 5, no. 5 (2013): 1656-1658. https://doi.org/10.3892/ol.2013.1228